Pages, Columns, Lines where

Figures Appear

Relevant Passages or Relevant

Pages, Columns, Lines

Passages or Relevant

where Relevant

Figures Appear

U.S. Patent and Trademark.
Under the Paperwork Reduction Act of 1986, no persons are required to respond to a collection of information and act of 1986.

Code¹ Issue Date

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Patent Number

Foreign Document

Examiner Cite

Initial* No

Application Number		10774039		
Filing Date		2004-02-06		
First Named Inventor Mitch		ell B. Mikula		
Art Unit		2673		
Examiner Name				
Attorney Docket Number		5760-20400		

Name of Patentee or

Applicant of cited

Document

1	6535998		2003-03-18	Cabrera, et al.	
2	6729011		2001-08-21	Muhlestein	
to ac	dd additional U.S. Pate				
Cite No	Publication Number	Kind Code ¹		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
1					
	h to a	2 6729011 h to add additional U.S. Patel Cite Dublication Number	2 6729011 to add additional U.S. Patent citatio U.S.P	2 6728011 2001-08-21 to add additional U.S. Patent citation information pr U.S.PATENT APPLJ Cite Dishination Number Kind Publication	2 6728011 2001-08-21 Muhierdein To add additional U.S. Patent citation information please citic the Add button. U.S.PATENT APPLICATION PUBLICATIONS Citie Diskindrion Mumbur Kind Publication Name of Patentee or Applicant

FOREIGN PATENT DOCUMENTS

Kind Publication

Code⁴ Date

U.S.PATENTS

Name of Patentee or Applicant

of cited Document

If you wish to add additional Foreign Patent Document citation information please click the Add button

Country

Code2 i

NON-PATENT LITERATURE DOCUMENTS

Examiner Cite

Initial* No Number3

10774030 Application Number Filing Date 2004-02-06 INFORMATION DISCLOSURE First Named Inventor Mitchell B. Mikula STATEMENT BY APPLICANT Art I Init 2673 (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 5760-20400

Examiner Initials*	Cite No						
	1						

If you wish to add additional non-patent literature document citation information please click the Add button

Date Considered

FYAMINER SIGNATURE *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Petent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Jaconese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document 4 Kind of document by the expropriete symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to piece a check mark here if English lenguege trensletion is etteched.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10774039	
Filing Date		2004-02-06	
First Named Inventor	Mitchell B. Mikula		
Art Unit		2673	
Examiner Name			
Attorney Docket Number		5760-20400	

CERTIFICATION STATEMENT

Diagon one 27	CED 1	07 and 5	1 98 to make th	a annonniata	anination(a):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFR 197(a)(1)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signify the certification after making reasonable inclusify, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(e)(2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Lawrence J. Merkel/	Date (YYYY-MM-DD)	2007-02-05
Name/Print	Lawrence J. Merkel	Registration Number	41191

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file find by the USPTO to process) an application. Confidentially is gowered by \$5.1.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Them will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradentant Office, u.S. operatment of Commence, P. 0.8b 1456, Alexandri, V.S. 22313-1450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. 8bx 1450, Alexandria, VA.22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. 2-95-79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is SS U.S.C. 2(b)(2); (2) furnishing of the information solicided is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine you submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine you submission related to a patient agricultant or patient. If you do not furnish the requested required to the processing of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
 (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
 Department of Justice to determine where the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodistrions.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursulant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designe, cuting an inspection of records concluded by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make.
- 3. A record from this system of records may be disclosed, as a routine use, be the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public insepticions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.